Alchemia (ASX: ACL) announces Initiation of P2 trial in Small Cell Lung Cancer
September 12th, 2011
No comments
ASX: ACL is about to initiate recruitment to a 390 patient pivotal P3 study of HA-Irinotecan in metastatic colorectal (bowel) cancer. Read more…
